bannerHON
img
HONnews
HONnews
img PATIENT / PARTICULIER img PROFESSIONNEL DE SANTE img WEBMESTRE img
img
 
img
HONcode sites
All Web sites
HONselect
News
Conferences
Images

Themes:
A B C D E F G H I
J K L M N O P Q
R S T U V W X Y Z
Browse archive:
2014: S A J J M A M F J
2013: D N O S

 
  Other news for:
Hepatitis
 Resources from HONselect
Olysio Approved as Hepatitis C Treatment
Drug blocks protein that helps virus replicate

By Scott Roberts

MONDAY, Nov. 25, 2013 (HealthDay News) -- Olysio (simeprevir) has been approved by the U.S. Food and Drug Administration to treat chronic hepatitis C infection in adults.

The hepatitis C virus causes inflammation of the liver, which can inhibit the organ's function and ultimately lead to deadly liver failure. Most people have no symptoms until the virus causes liver damage, the agency said in a news release. Complications of the disease, which affects some 3.2 million Americans, could include a yellowing of the eyes and skin known as jaundice, abdominal fluid accumulation or liver cancer.

The new drug was approved to be used with two other antiviral medications to treat people who have cirrhosis but whose liver is still functioning, people who haven't been treated for hepatitis C previously, or for people who haven't responded to other therapies, the FDA said. The new drug should only be used in combination with peginterferon-alfa and ribavirin, and should not be administered by itself, the agency warned.

Olysio, combined with the other two drugs, was evaluated in clinical studies involving more than 2,000 people. Common side effects included rash, itching and nausea. Noting the potential for serious reactions involving light exposure, users are advised to avoid the sun and to use sunscreen and other protective measures during treatment, the FDA said.

Olysio is marketed by Raritan, N.J.-based Janssen Pharmaceuticals.

More information

The U.S. Centers for Disease Control and Prevention has more about hepatitis C.

Copyright © 2013 HealthDay. All rights reserved. URL:http://consumer.healthday.com/Article.asp?AID=682515

Resources from HONselect: HONselect is the HON's medical search engine. It retrieves scientific articles, images, conferences and web sites on the selected subject.
Hepatitis
Hepatitis C
Therapeutics
Liver
Infection
Adult
Affect
Lead
The list of medical terms above are retrieved automatically from the article.

Disclaimer: The text presented on this page is not a substitute for professional medical advice. It is for your information only and may not represent your true individual medical situation. Do not hesitate to consult your healthcare provider if you have any questions or concerns. Do not use this information to diagnose or treat a health problem or disease without consulting a qualified healthcare professional.
Be advised that HealthDay articles are derived from various sources and may not reflect your own country regulations. The Health On the Net Foundation does not endorse opinions, products, or services that may appear in HealthDay articles.


Home img About us img MediaCorner img HON newsletter img Site map img Ethical policies img Contact